XARELTO®: Chronic coronary artery disease and peripheral artery disease treatment

XARELTO® 2.5 mg VASCULAR DOSE*:Significantly reduced a composite of cv death, mi, and stroke† in combination with aspirin in patients with chronic CAD or PAD1

For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.

*XARELTO® 2.5 mg twice daily with aspirin 100 mg once daily.

Major cardiovascular events were a composite of cardiovascular death, myocardial infarction, or stroke.

CAD = coronary artery disease; CV = cardiovascular; MI = myocardial infarction; PAD = peripheral artery disease.